Direct democracy Switzerland: How To
Your browser is out of date. It has known security flaws and may not display all features of this websites. Learn how to update your browser[Close]


Companies, government reach drug pricing deal

Medicines are up to 50 per cent higher in Switzerland than abroad, according to studies (Keystone)

Medicines are up to 50 per cent higher in Switzerland than abroad, according to studies


In an effort to improve drug affordability and access, the Swiss government and the pharmaceutical industry have struck a short-term deal: drug makers will withdraw price-related lawsuits in exchange for a faster drug approval process.

Studies show drug prices in Switzerland are as much as 50 per cent higher than beyond its borders, and drug companies have long played defence against government plans intended to bring down prices.

Interior minister Alain Berset, whose portfolio includes health matters, welcomed the deal as “very good, balanced and mutually acceptable solution.”

Speaking at a news conference on Friday, Berset said patients would save up to CHF720 million ($773 million) over the next couple of years.

Walter Hölzle, president of the Association of Pharmaceutical Companies in Switzerland (Vips), stressed that the agreement included a pledge to significantly shorten the approval procedure of new drugs to 60 days.

"The agreement represents a major and important step towards early implementation of needed reforms in the current price system,” he said.

Thomas Cueni, a senior official of Interpharma representing ten major pharmaceutical companies, added the price cuts were a temporary concession to reach a deal.

“We had to swallow that pill also because the health insurance companies have already factored them in,” he told journalists.

Trading off

The agreement is set to come into force on June 1 but will only last through the end of 2014, at which point the deal will be re-examined.

The price reduction could also lead to a slight drop in health premiums according to the Health lnsurance Association, santésuisse.

A call from cabinet in the spring of 2012 to peg prices to the international market was met with legal action from pharmaceutical companies.

They argued the newly mandated drug prices did not sufficiently take into account the therapeutic benefits of each drug.

Under the deal announced on Friday, drug companies will adhere to cabinet’s recommendation of pegging Swiss drug costs to overseas prices. They also promised to drop all current and future price-related lawsuits. and agencies


It is only permitted to use a hyperlink to specific SWI content on the website of the party requesting the content or the website of a third party. The framing of content from SWI is only allowed if it is unchanged, without advertising.

Articles can be copied and used if these guidelines are followed:

The article can only be used if it clearly mentions “[author],” For any further use, please send an email to: The editorial content on SWI adheres to the guidelines, rights and duties specified by the Swiss Press Council. If content not adhering to those outlined by the Press Council are found on third-party website displaying SWI content, SWI can demand that all SWI content be removed from the corresponding pages.